Guideline-directed testosterone therapy, when judiciously prescribed, can reverse many perturbations of hypogonadism while converging evidence including from recent large-scale randomized controlled trials demonstrates that modern testosterone therapy does not augment cardiovascular risk or mortality.
Key Findings
Background
Aging per se does not precipitate hypogonadism; rather, age-associated comorbidities catalyze the emergence of functional hypogonadism.
Functional hypogonadism arises from comorbid states such as obesity and type 2 diabetes mellitus rather than from aging itself.
Origins of testosterone deficiency may lie in testicular insufficiency, hypothalamic-pituitary dysfunction, or functional hypogonadism.
The paper distinguishes between primary, secondary, and functional hypogonadism as distinct etiological categories.
Results
Epidemiological data corroborate a bidirectional nexus between functional hypogonadism and the metabolic syndrome, both being harbingers of increased cardiovascular mortality.
The relationship between functional hypogonadism and metabolic syndrome is described as bidirectional.
Both functional hypogonadism and metabolic syndrome are identified as harbingers of increased cardiovascular mortality.
Data from recent randomized trials and large-scale observational studies were used to characterize this relationship.
Results
Hypogonadism commonly manifests through a broad spectrum of somatic and psychosocial impairments that markedly degrade quality of life.
Manifestations include disturbances of mood and cognition (including depression, fatigue, and mental decline).
Sexual dysfunction manifestations include diminished libido and impaired erectile capacity.
Additional manifestations include disproportionate visceral adiposity, sarcopenia, osteopenia or osteoporosis, and anemia.
These cumulative impairments are described as markedly degrading quality of life.
Results
Modern testosterone therapy does not augment cardiovascular risk or mortality, according to converging evidence including from recent large-scale randomized controlled trials.
Evidence includes data from recent large-scale randomized controlled trials.
The paper states testosterone therapy 'does not augment cardiovascular risk or mortality.'
On the contrary, testosterone therapy is described as conferring 'tangible metabolic and quality-of-life advantages, even in advanced age.'
Benefits are conditional upon coexistent conditions being addressed concomitantly.
Results
Guideline-directed testosterone therapy can reverse many perturbations associated with hypogonadism across multiple physiological domains.
Testosterone therapy is described as ameliorating sexual function, mood, vitality, muscle mass, bone density, and anemia.
Therapy also mitigates metabolic derangement.
Optimal outcomes hinge upon meticulous patient selection and exclusion of contraindications.
Contraindications include active prostate carcinoma or current fertility intention.
Vigilant monitoring of prostate health and hematocrit is required.
Conclusions
Testosterone therapy is identified as a safe and efficacious means of restoring androgen sufficiency when applied with discernment and appropriate patient selection.
Safety profile requires exclusion of contraindications such as active prostate carcinoma or current fertility intention.
Monitoring requirements include vigilant surveillance of prostate health and hematocrit.
The paper concludes testosterone therapy offers benefits 'even in advanced age' provided coexistent conditions are addressed.
The review characterizes the therapeutic approach as enhancing 'male health and well-being in its fullest sense.'
Zitzmann M, Soave A, Bier S. (2026). Functional testosterone deficiency in aging men: Clinical impact, diagnostic pathways, and treatment strategies.. Maturitas. https://doi.org/10.1016/j.maturitas.2026.108870